Priya Jain
About Priya Jain
Priya Jain is the Vice President and Head of Pharmacovigilance at Deciphera Pharmaceuticals, where she has worked since 2021. She has extensive experience in drug safety and pharmacovigilance, having held various positions at notable pharmaceutical companies including Alkermes and ARIAD Pharmaceuticals.
Current Role at Deciphera Pharmaceuticals
Priya Jain serves as the Vice President and Head of Pharmacovigilance at Deciphera Pharmaceuticals. She has held this position since 2021, contributing to the company's commitment to drug safety and monitoring. In this role, she oversees the pharmacovigilance operations, ensuring compliance with regulatory requirements and the safety of pharmaceutical products.
Previous Experience at Alkermes
Prior to her current position, Priya Jain worked at Alkermes as the Medical Director of Drug Safety and Pharmacovigilance from 2015 to 2019. During her four years at the Waltham location, she was responsible for managing drug safety assessments and developing pharmacovigilance strategies.
Educational Background
Priya Jain studied at Al-Ameen Medical College in India, where she earned her MBBS, equivalent to a Doctor of Medicine (MD). She also pursued further studies at the Massachusetts Institute of Technology, enhancing her knowledge in medical and scientific fields.
Career Progression in Pharmacovigilance
Priya Jain has extensive experience in pharmacovigilance, having worked in various roles across multiple organizations. She served as a Pharmacovigilance Scientist at ARIAD Pharmaceuticals, Inc. from 2014 to 2015, and as a Senior Associate in Drug Safety and Pharmacovigilance at Asahi Kasei Pharma America from 2012 to 2013. Her career also includes a position as Manager of Pharmacovigilance and Drug Safety at TESARO, Inc. from 2013 to 2014.
Early Career Experience
Priya Jain began her career in clinical research as a Senior Clinical Research Associate at Tufts-New England Medical Center from 2008 to 2010. She also worked at PAREXEL as a Drug Safety Associate from 2011 to 2012, gaining foundational experience in drug safety and clinical trials.